's () chief executive Richard Hullihen talks Proactive London's Andrew Scott through the firm's 2018 results.
Polarean reported slightly higher revenues and lower costs than expected for the past calendar year.
It's currently taking its drug-and-device technology through late-stage clinical trials and he says they're on track to apply for regulatory permission in the US next year and deliver first commercial sales by end of the year.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE